ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 751.7 USD | +0.13% |
|
-1.36% | +28.54% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
750.8
USD
Average target price
813.3
USD
Spread / Average Target
+8.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.54% | 676B | |
| +24.15% | 554B | |
| -7.37% | 349B | |
| +14.43% | 318B | |
| +7.60% | 291B | |
| +3.06% | 210B | |
| -0.35% | 204B | |
| -10.02% | 194B | |
| -11.79% | 144B | |
| -7.89% | 142B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly, Entos Pharmaceuticals Partner To Develop Therapies For Multiple Neurologic Indications
